Dr. LI Cho Wing, Bryan
MBBS (HK), MRCP (UK), FHKCP, FHKAM (Med)
Associate Consultant (Grantham hospital)
Honorary Clinical Assistant Professor
Biography
Dr Li graduated from the University of Hong Kong, Faculty of Medicine in 2004. He received basic physician training and higher physician training in Department of Medicine, Queen Mary Hospital. He was admitted as fellow of internal medicine in 2012, after completing both Advance Internal Medicine and Palliative Medicine specialist training. He then worked as resident specialist and associate consultant in Palliative Medical Unit, Grantham Hospital. Dr Li underwent specialist training in Medical Oncology in Queen Mary Hospital from 2018 and was accredited as specialist in Medical Oncology in 2020.
Five Most Representative Publications
1) Li BC, Chiu J, Shing K, Kwok GG, Tang V, Leung R, Ma KW, She WH, Tsang J, Chan A, Cheung TT.
The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.
Advances in Therapy. 2021 Jun 1:1-1.
[Citation: - ] [IF: 3.85 (JCR 2020)]
2) Wong CY, Leung R, Kwok GW, Tsang J, Li B, Yau T, Chiu J.
Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer
Postgrad Med J. 2021 May 26. doi:10.1136/postgradmedj-2021-140319
[Citation: -] [IF: 2.40 (JCR 2020)]
3) Wong JS, Dong Y, Tang V, Leung T, Yeung CSY, Tai A, Law A, Shum T, Kwok GG, Li BC, Leung R, Chiu J, Ma KW, She WH, Tsang J, Cheung TT, Yau T
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
Cancers (Basel). 2021 Apr 21;13(9):2002.
[Citation: - ] [IF: 6.64 (JCR 2020)]
4) Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.
Cancers (Basel). 2021 Apr 18;13(8):1949.
[Citation: - ] [IF: 6.64 (JCR 2020)]
5) Tsang J, Wong JSL, Kwok GGW, Li BCW, Leung R, Chiu J, Cheung TT, Yau T.
Drug Profile: Nivolumab plus Ipilimumab for Patients with Hepatocellular Carcinoma previously treated with Sorafenib
Expert Review of Gastroenterology & Hepatology 2021 Mar 5
[Citation: 2 ] [IF: 3.87 (JCR 2020)]